These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36944065)

  • 1. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
    Tieger MG; Eliott D; Cakir B; Dahrouj M
    Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bilateral Nivolumab-associated Vogt-Koyanagi-Harada-like Uveitis in a Patient with Metastatic Renal Cell Carcinoma].
    Czichos C; Wawrzynów B; Chamalis C; von Jagow B
    Klin Monbl Augenheilkd; 2021 Jun; 238(6):711-714. PubMed ID: 33395707
    [No Abstract]   [Full Text] [Related]  

  • 3. BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION MISTAKEN FOR NIVOLUMAB-INDUCED VOGT-KOYANAGI-HARADA DISEASE-LIKE SYNDROME.
    Dallinga MG; Bolhuis K; Bins A; de Hoog J
    Retin Cases Brief Rep; 2024 May; 18(3):332-336. PubMed ID: 36728009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
    Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
    Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
    [No Abstract]   [Full Text] [Related]  

  • 5. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
    Madoe A; Schauwvlieghe PP; Jacob J
    Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
    Ushio R; Yamamoto M; Miyasaka A; Muraoka T; Kanaoka H; Tamura H; Kaneko A; Izawa A; Hirama N; Teranishi S; Manabe S; Inoue T; Shibata K; Sugiura Y; Kudo M; Kaneko T
    Intern Med; 2021 Nov; 60(22):3593-3598. PubMed ID: 34092725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
    Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
    Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
    [No Abstract]   [Full Text] [Related]  

  • 8. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
    Kikuchi R; Kawagoe T; Hotta K
    BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
    Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
    Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.
    Noble CW; Gangaputra SS; Thompson IA; Yuan A; Apolo AB; Lee JM; Papaliodis GN; Kodati S; Bishop R; Magone MT; Sobrin L; Sen HN
    Ocul Immunol Inflamm; 2020 Aug; 28(6):854-859. PubMed ID: 31013173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy.
    Matsuo T; Masuda I; Ota K; Yamadori I; Sunami R; Nose S
    Acta Med Okayama; 2007 Oct; 61(5):305-9. PubMed ID: 17971847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 13. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
    Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
    Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
    Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
    Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.
    Zhang Q; Fan X; Tian M; Han H
    BMC Nephrol; 2020 Jul; 21(1):272. PubMed ID: 32660433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
    Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
    Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
    Wang JN; Zhang Y; Huang CY; Li K; Yu XB
    BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
    Witmer MT
    Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
    Mihailovic N; Dyballa J; Herz S; Fluck M; Alnawaiseh M; Merté RL; Eter N
    Ophthalmologe; 2020 May; 117(5):467-471. PubMed ID: 31489479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.